Alkermes (ALKS) Set to Post Quarterly Earnings on Tuesday

Alkermes (NASDAQ:ALKS) is anticipated to post its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Alkermes to announce earnings of ($0.0815) per share and revenue of $463.48 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Alkermes Stock Performance

Shares of Alkermes stock opened at $45.34 on Friday. Alkermes has a one year low of $27.00 and a one year high of $55.67. The firm has a market capitalization of $7.61 billion, a price-to-earnings ratio of 119.32 and a beta of 0.32. The business has a 50-day simple moving average of $44.06 and a 200 day simple moving average of $40.44. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.30 and a quick ratio of 1.85.

Insider Buying and Selling at Alkermes

In other Alkermes news, Director Nancy Lynn Md Snyderman sold 44,472 shares of Alkermes stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $50.35, for a total transaction of $2,239,165.20. Following the completion of the transaction, the director owned 15,395 shares in the company, valued at approximately $775,138.25. The trade was a 74.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Craig C. Hopkinson sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $48.58, for a total value of $437,220.00. Following the sale, the executive vice president directly owned 69,389 shares of the company’s stock, valued at $3,370,917.62. This represents a 11.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 76,150 shares of company stock worth $3,752,181 in the last quarter. 4.59% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on ALKS shares. Robert W. Baird raised their price objective on Alkermes from $58.00 to $61.00 and gave the company an “outperform” rating in a research note on Tuesday, September 22nd. Stifel Nicolaus reaffirmed a “buy” rating and set a $63.00 target price (up from $45.00) on shares of Alkermes in a research report on Monday, July 20th. TD Cowen reiterated a “buy” rating on shares of Alkermes in a report on Monday, September 21st. Needham & Company LLC reissued a “buy” rating and issued a $62.00 price target on shares of Alkermes in a research report on Monday, September 21st. Finally, HC Wainwright reissued a “neutral” rating on shares of Alkermes in a research report on Monday, September 21st. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $54.38.

About Alkermes

Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its research and development activities address conditions including schizophrenia, bipolar disorder, addiction, depression and other neuropsychiatric disorders.

The company’s marketed products include Vivitrol, an extended-release injectable form of naltrexone used to treat alcohol dependence and prevent relapse to opioid dependence; Aristada and Aristada Initio, long-acting injectable formulations of aripiprazole lauroxil for the treatment of schizophrenia; and Lybalvi, a combination of olanzapine and samidorphan approved for schizophrenia and bipolar I disorder in adults.

Founded in 1987, Alkermes is incorporated in Ireland and maintains its corporate headquarters in Waltham, Massachusetts.